Endocannabinoid reuptake inhibitor

Endocannabinoid reuptake inhibitors (ERIs) are a class of drugs that elevate the levels of endocannabinoids in the body. They function by inhibiting the reuptake and degradation of endocannabinoids, which are naturally occurring substances in the body that bind to cannabinoid receptors.

Mechanism of Action

ERIs work by blocking the reuptake of endocannabinoids into the neuron, thereby increasing their concentration in the synaptic cleft. This leads to an increased activation of cannabinoid receptors, which are part of the endocannabinoid system. The endocannabinoid system plays a crucial role in regulating a variety of physiological and cognitive processes including fertility, pregnancy, appetite, pain-sensation, mood, and memory.

Therapeutic Uses

ERIs have potential therapeutic uses in a variety of conditions including chronic pain, neurodegenerative diseases, mood disorders, and cancer. They may also have potential in treating obesity and metabolic syndrome, due to the role of the endocannabinoid system in regulating appetite and energy balance.

Side Effects

As with all drugs, ERIs can have side effects. These can include dizziness, dry mouth, and changes in appetite. However, these side effects are generally mild and often diminish over time.

Research and Development

Research into ERIs is ongoing, with several drugs currently in clinical trials. These include AM404, a derivative of paracetamol that inhibits the reuptake of the endocannabinoid anandamide, and URB597, which inhibits the enzyme fatty acid amide hydrolase (FAAH), responsible for the degradation of anandamide.

See Also

• Cannabinoid receptor
• Endocannabinoid system
• Cannabinoid
• Anandamide
• Fatty acid amide hydrolase

This article is a stub related to pharmacology. You can help WikiMD by expanding it!